- Home
- ZYME vs TXO Comparison
ZYME vs TXO Comparison
Compare ZYME & TXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- TXO
- Stock Information
- Founded
- ZYME 2003
- TXO 2012
- Country
- ZYME United States
- TXO United States
- Employees
- ZYME N/A
- TXO N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- TXO Oil & Gas Production
- Sector
- ZYME Health Care
- TXO Energy
- Exchange
- ZYME Nasdaq
- TXO Nasdaq
- Market Cap
- ZYME 846.1M
- TXO 699.0M
- IPO Year
- ZYME 2017
- TXO 2023
- Fundamental
- Price
- ZYME $11.31
- TXO $17.05
- Analyst Decision
- ZYME Buy
- TXO
- Analyst Count
- ZYME 6
- TXO 0
- Target Price
- ZYME $19.50
- TXO N/A
- AVG Volume (30 Days)
- ZYME 553.2K
- TXO 73.0K
- Earning Date
- ZYME 05-08-2025
- TXO 05-01-2025
- Dividend Yield
- ZYME N/A
- TXO 14.11%
- EPS Growth
- ZYME N/A
- TXO N/A
- EPS
- ZYME N/A
- TXO 0.40
- Revenue
- ZYME $93,384,000.00
- TXO $299,696,000.00
- Revenue This Year
- ZYME $26.29
- TXO $21.35
- Revenue Next Year
- ZYME $75.78
- TXO N/A
- P/E Ratio
- ZYME N/A
- TXO $42.34
- Revenue Growth
- ZYME 85.05
- TXO 3.43
- 52 Week Low
- ZYME $8.21
- TXO $15.22
- 52 Week High
- ZYME $17.70
- TXO $23.56
- Technical
- Relative Strength Index (RSI)
- ZYME 40.96
- TXO 46.19
- Support Level
- ZYME $10.86
- TXO $16.86
- Resistance Level
- ZYME $13.23
- TXO $17.38
- Average True Range (ATR)
- ZYME 0.56
- TXO 0.46
- MACD
- ZYME -0.10
- TXO 0.11
- Stochastic Oscillator
- ZYME 18.78
- TXO 61.36
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About TXO TXO Partners L.P.
TXO Partners LP is focused on the acquisition, development, optimization, and exploitation of oil, natural gas, and natural gas liquid reserves in North America.